Rational design of formulated DNA vaccines: The DermaVir approach

Gene Vaccines

Volumn , Issue , 2014, Pages 127-143

  Nátz, Eszter ^a   Lisziewicz, Julianna ^a  

^a Genetic Immunity   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860237099     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0439-2_6     Document Type: Chapter

References (62)

1. Abdulhaqq SA, Weiner DB (2008) DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42(1-3):219-232
2. Ada G (2005) Overview of vaccines and vaccination. Mol Biotechnol 29(3):255-272
3. Anderson RJ, Schneider J (2007) Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25(Suppl 2):B24-B34
4. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S (2003) Induction of immune responses by DNA vaccines in large animals. Vaccine 21(7-8):649-658
5. Bauer J, Bahmer FA, Worl J, Neuhuber W, Schuler G, Fartasch M (2001) A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope. J Invest Dermatol 116(2):313-318
6. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD (2006) Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 24(21):4582-4585
7. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92(16):7297-7301
8. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653):1881-1893
9. Calarota SA, Weiner DB, Lori F, Lisziewicz J (2007) Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine 25(16):3070-3074
10. Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F (2008) HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 180(9):5907-5915
11. Choosakoonkriang S, Lobo BA, Koe GS, Koe JG, Middaugh CR (2003) Biophysical characterization of PEI/DNA complexes. J Pharm Sci 92(8):1710-1722
12. Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S, Restrepo S, Suschak J, Ferrari MG, Chung HK, Kalyanaraman VS, Markham P, Pal R (2007) HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 366(1):197-211
13. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML (2001) West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75(9):4040-4047
14. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997) DNA vaccines. Annu Rev Immunol 15:617-648
15. Douek DC, Kwong PD, Nabel GJ (2006) The rational design of an AIDS vaccine. Cell 124(4):677-681
16. Ellenberger D, Wyatt L, Li B, Buge S, Lanier N, Rodriguez IV, Sariol CA, Martinez M, Monsour M, Vogt J, Smith J, Otten R, Montefiori D, Kraiselburd E, Moss B, Robinson H, McNicholl J, Butera S (2005) Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1(CRF02-AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 340(1):21-32
17. Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378
18. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13(1):100-106
19. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928-1943
20. Garver KA, LaPatra SE, Kurath G (2005) Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O.nerka salmon. Dis Aquat Organ 64(1):13-22
21. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422
22. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, Webster DP, Dunachie SJ, Moorthy VS, McConkey SJ, Gilbert SC, Hill AV (2005) Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 175(9):5675-5680
23. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360(18):1815-1826
24. Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D, McCune JM (2008) Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol 180(12):7907-7918
25. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, Schwartz O (1998) Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8(4):483-495
26. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F (1999) Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 340(21):1683-1684
27. Lisziewicz J, Gabrilovich DI, Varga G, Xu J, Greenberg PD, Arya SK, Bosch M, Behr JP, Lori F (2001) Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol 75(16):7621-7628
28. Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F (2005a) DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol 124(1):160-169
29. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F (2005b) Control of viral rebound through therapeutic immunization with DermaVir. AIDS 19(1):35-43
30. Lisziewicz J, Calarota S, Banhegyi D, Lisziewicz Z, Ujhelyi E, Lori F (2008) Single DermaVir patch treatment of HIV+ individuals induces long-lasting, high-magnitude, and broad HIVspecific T cell responses. Paper presented at the 15th conference on retroviruses and opportunistic infections, Boston, MA, 3-6 Feb. 2008
31. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS (2010) Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 16(2):224-227
32. Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J (2000) Control of SIV rebound through structured treatment interruptions during early infection. Science 290(5496):1591-1593
33. Matzinger P (2002) The danger model: a renewed sense of self. Science 296(5566):301-305
34. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467(7315):591-595
35. NCT00270205 Safety and tolerability of and immune response to LC002, an experimental therapeutic vaccine, in adults receiving anti-HIV treatment. http://clinicaltrials.gov/ct2/show/NCT00270205. Accessed July 2011
36. NCT00711230 DermaVir patch (LC002) in HIV-1 infected treatment-naïve patients. http://clinicaltrials.gov/ct2/show/NCT00711230. Accessed July 2011
37. NCT00918840 antiretroviral-sparing concept: investigate the effect of therapeutic immunization with DermaVir patch. http://clinicaltrials.gov/ct2/show/NCT00918840. Accessed July 2011
38. Nicolas JF, Guy B (2008) Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 7(8):1201-1214
39. Ohana P, Gofrit O, Ayesh S, Al-Sharef W, Mizrahi A, Birman T, Schneider T, Matouk I, de Groot N, Tavdy E, Sidi A, Hochberg A (2004) Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer. Gene Ther Mol Biol 8:181-192
40. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, Greenacre M (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301-314
41. Peachman KK, Rao M, Alving CR (2003) Immunization with DNA through the skin. Methods 31(3):232-242
42. Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F (2002) Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. J Virol 76(5):2274-2278
43. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN (1998) Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188(6):1075-1082
44. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H, Bower M (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27(6):884-890
45. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM (2008) A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26(26):3352-3361
46. Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3(5):445-450
47. Reddy ST, Swartz MA, Hubbell JA (2006) Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 27(12):573-579
48. Rodriguez B, Asmuth D, Matining R, Spritzler J, Li X, Jacobson J, Read S, Lisziewicz J, Lori F, Pollard R, Team AS (2010) Repeated-dose transdermal administration of DermaVir, a candidate plasmid DNA-based therapeutic HIV vaccine, is safe and well-tolerated: a 61-week analysis of ACTG study 5176. Paper presented at the XVIII international AIDS conference, Vienna, Austria
49. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198(10):1482-1490
50. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, Slama L, Simon A, Valantin MA, Thibault V, Autran B (2009) Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 23(16):2079-2089
51. Somogyi E, Xu J, Gudics A, Tóth J, Kovács A, Lori F, Lisziewicz J (2011) A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 29(4):744-53 doi:10.1016/j.vaccine.2010.11.019
52. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
53. Stevenson FK, Ottensmeier CH, Rice J (2010) DNA vaccines against cancer come of age. Curr Opin Immunol 22(2):264-270
54. Tang DC, DeVit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356(6365):152-154
55. Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R (2006) Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J Anim Sci 84(3):733-742
56. Toke ER, Lorincz O, Somogyi E, Lisziewicz J (2010) Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm 392(1-2):261-267
57. Tomalia DA (2009) In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 11:1251-1310
58. van Lunzen J, Pollard R, Stellbrink HJ, Plettenberg A, Natz E, Lisziewicz Z, Freese R, Molnar L, Calarota SA, Lori F, Lisziewicz J (2010) DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization. Paper presented at the XVIII international AIDS conference, Vienna, Austria
59. von Harpe A, Petersen H, Li Y, Kissel T (2000) Characterization of commercially available and synthesized polyethylenimines for gene delivery. J Control Release 69(2):309-322
60. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465-1468
61. Yang OO, Nguyen PT, Kalams SA, Dorfman T, Gottlinger HG, Stewart S, Chen IS, Threlkeld S, Walker BD (2002) Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 76(4):1626-1631
62. Zinkernagel RM (2000) Localization dose and time of antigens determine immune reactivity. Semin Immunol 12(3):163-171; discussion 257-344